SynapDx Corporation, Broad Institute Collaborate on NGS Analytics for Diagnostic Applications
News Mar 17, 2014
SynapDx Corporation today announced that it has formed a collaboration with the Broad Institute of Harvard and MIT. The collaboration brings together scientists with leading expertise in computational biology and software engineering to accelerate advances in next generation sequencing.
SynapDx is currently conducting one of the largest prospective, multi-center studies to analyze blood from children undergoing clinical evaluation for autism spectrum disorder (ASD). The objective of the collaboration is to develop advanced next generation sequencing (NGS) analysis techniques to further enhance test accuracy and clinical utility in autism diagnostics.
"We are thrilled to be working with SynapDx. Our collaboration will enable us to really push the methods for variant detection in new directions," said Eric Banks, Group Leader of Genome Sequencing and Analysis at the Broad Institute.
“Our partnership with the Broad Institute helps advance our mission by developing powerful tools for the analysis of next generation sequencing data that will have broad application in the detection of autism and beyond ,” said Mark DePristo, SynapDx Vice President of Informatics .
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.